Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON)
- 22 December 2015
- journal article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 18 (9) , 945-954
Abstract
To ascertain the level of agreement and achieve a consensus among cancer pain specialists in Spain with regard to the optimal definition, diagnosis, and management of breakthrough cancer pain (BTcP). Two-round Delphi methodology survey (February–May 2013) using seven-point Likert scales (ranging from 1 “strongly disagree” to 7 “strongly agree”) was carried out. Mean scores >5 or <3 indicated, respectively, agreement or disagreement. Scores from 3 to 5 indicated no consensus. A total of 126 experienced specialists were surveyed. Response rates were 68 % in round 1 and 90 % in round 2. Agreement (mean Likert score) was strongest for the proposed BTcP definition (6.6), the use of oral (6.1), and intranasal (6.0) transmucosal fentanyl, the need for early assessment after BTcP treatment initiation, and the need to improve staff knowledge of BTcP. Broad agreement was also reached regarding the need to systematically screen all cancer patients for BTcP (5.9). Most respondents (82 %) considered strong opioids to be appropriate treatment. In contrast, no consensus was reached regarding strong opioid treatment for baseline pain as a prerequisite for BTcP diagnosis. Consensus was strong for most treatment, and diagnostic aspects were evaluated in the study. However, several important issues remain unresolved, particularly whether the diagnostic criteria must include strong opioids for background pain. Nurses’ awareness and understanding of BTcP was considered insufficient, and more training is needed in this area. Overall, agreement among specialists was good, but more work is needed to better define the optimal diagnostic features and treatments for this condition.Keywords
This publication has 48 references indexed in Scilit:
- Breakthrough cancer pain – still a challengeJournal of Pain Research, 2012
- Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCThe Lancet Oncology, 2012
- Newer Generation Fentanyl Transmucosal Products for Breakthrough Pain in Opioid-Tolerant Cancer PatientsClinical Drug Investigation, 2011
- Integrated strategies for the successful management of breakthrough cancer painCurrent Opinion in Supportive & Palliative Care, 2011
- Epidemiology and Pattern of Care of Breakthrough Cancer Pain in a Longitudinal Sample of Cancer PatientsThe Clinical Journal of Pain, 2011
- How do nurses assess and manage breakthrough pain in specialist palliative care inpatient units? A multicentre studyPalliative Medicine, 2009
- The Alberta Breakthrough Pain Assessment Tool for Cancer Patients: A Validation Study Using a Delphi Process and Patient Think-Aloud InterviewsJournal of Pain and Symptom Management, 2008
- Prevalence of pain in patients with cancer: a systematic review of the past 40 yearsAnnals of Oncology, 2007
- Breakthrough Cancer PainJournal of Pain and Symptom Management, 2002
- An international survey of cancer pain characteristics and syndromesPain, 1999